Johnson & Johnson (JNJ) announces FDA approval of icotyde (icotrokinra) ushers in new Era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

• Met all primary efficacy endpoints in four phase 3 studies with 2,500 patients.
• Adverse reactions for icotyde within 1.1% of placebo through week 16; no new safety signals through week 52.

Johnson & Johnson's FDA approval for icotyde represents a significant advancement in the treatment of plaque psoriasis, marking a pivotal shift in their pharmaceutical offerings. Meeting primary efficacy endpoints across multiple trials with a favorable safety profile, this approval could enhance JNJ's market position and revenue potential in the highly competitive dermatology space.